Vericel (NASDAQ:VCEL) was downgraded by investment analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued on Friday.

A number of other research analysts have also issued reports on VCEL. Piper Jaffray Companies reaffirmed a “buy” rating and set a $7.00 target price on shares of Vericel in a report on Thursday, August 10th. BTIG Research set a $6.00 target price on Vericel and gave the stock a “buy” rating in a report on Wednesday, August 9th.

Shares of Vericel (NASDAQ VCEL) traded up $0.05 on Friday, hitting $4.50. The stock had a trading volume of 633,705 shares, compared to its average volume of 500,141. Vericel has a 52 week low of $2.25 and a 52 week high of $6.30. The company has a current ratio of 2.50, a quick ratio of 2.22 and a debt-to-equity ratio of 0.44.

Vericel (NASDAQ:VCEL) last released its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.01. The firm had revenue of $14.26 million for the quarter. Vericel had a negative return on equity of 265.45% and a negative net margin of 45.11%. sell-side analysts anticipate that Vericel will post -0.6 EPS for the current year.

Several large investors have recently added to or reduced their stakes in the stock. Citadel Advisors LLC acquired a new position in shares of Vericel in the 3rd quarter valued at $235,000. Archon Capital Management LLC boosted its position in shares of Vericel by 95.7% in the 3rd quarter. Archon Capital Management LLC now owns 2,617,004 shares of the biotechnology company’s stock valued at $15,702,000 after purchasing an additional 1,279,925 shares during the period. JPMorgan Chase & Co. acquired a new position in shares of Vericel in the 3rd quarter valued at $328,000. EAM Investors LLC acquired a new position in shares of Vericel in the 3rd quarter valued at $943,000. Finally, Perkins Capital Management Inc. boosted its position in shares of Vericel by 118.4% in the 3rd quarter. Perkins Capital Management Inc. now owns 562,600 shares of the biotechnology company’s stock valued at $3,376,000 after purchasing an additional 305,000 shares during the period. Institutional investors and hedge funds own 33.17% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/12/01/vericel-vcel-lowered-to-sell-at-valuengine.html.

Vericel Company Profile

Vericel Corporation, formerly Aastrom Biosciences, Inc, is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Vericel Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel Corporation and related companies with MarketBeat.com's FREE daily email newsletter.